2024-10-15 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis Report

**1. Performance Comparison:**

Gilead Sciences Inc. (GILD) has underperformed the S&P 500 (VOO) significantly. While the S&P 500 has delivered a cumulative return of 135.82%, GILD has seen a negative return of -11.95%. This translates to a substantial underperformance of -147.77%, which places it at the 5.09th percentile of its historical underperformance range. 

**2. Recent Price Movement:**

* **Closing price:** $84.95
* **5-day moving average:** $85.15
* **20-day moving average:** $84.13
* **60-day moving average:** $79.07

The stock price is currently trading slightly below its 5-day moving average, indicating a potential short-term bearish sentiment. However, it is above its 20-day and 60-day moving averages, suggesting a longer-term upward trend.

**3. Technical Indicators:**

* **RSI:** 55.23 
* **PPO:** -0.21
* **Delta_Previous_Relative_Divergence:** -2.63, indicating a short-term downward trend.
* **Expected Return:** 0.0%. The expected return is based on a maximum 5-year forecast against the S&P 500 (VOO), suggesting no significant outperformance potential.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report for the quarter ending August 08, 2024, shows an EPS of 1.29, exceeding analysts' expectations. This positive earnings surprise could suggest a potential upside for the stock price. However, it's important to note the fluctuating earnings trend over the past few quarters, which could indicate a period of volatility.

**5. News and Recent Issues:**

Gilead Sciences Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for life-threatening diseases. 

* **Recent Market Outlook:** GILD's stock has been affected by the ongoing competition in the antiviral market. The company has been facing challenges in maintaining its market share for its key HIV and hepatitis C drugs. 
* **Analyst Opinions:** Analysts are divided on GILD's future prospects. Some believe the company's pipeline of new drugs and its efforts to expand into new therapeutic areas have the potential to drive growth. Others are concerned about the company's dependence on a few blockbuster drugs and the intense competition in the industry.
* **Performance Highlights:** GILD has been working to diversify its portfolio and develop new drugs for areas such as oncology, inflammation, and immunology. However, the company's recent performance has been uneven.

**6. Summary:**

Gilead Sciences Inc. has faced challenges in recent years, but its recent earnings results suggest potential for future growth. However, the stock's performance is heavily influenced by factors such as competition in the antiviral market and the success of its pipeline of new drugs. The company's high dependence on a few blockbuster drugs makes it susceptible to market volatility. Investors should consider the risks and potential rewards before making an investment decision.

**7. Recommendations:**

* **Long-Term Perspective:** Investors with a long-term perspective may find GILD's current valuation attractive. However, it's important to monitor the company's progress in developing its pipeline and its ability to compete effectively in the market.
* **Short-Term Trading:** The stock's recent price movement and technical indicators suggest short-term volatility. Traders should use caution when making short-term trades, as the stock may experience significant fluctuations. 
* **Diversification:** Investors should consider diversifying their portfolios with other stocks in the healthcare sector to mitigate the risk associated with GILD.

**Disclaimer:** This analysis is based on publicly available information and should not be construed as financial advice. Investors are advised to conduct their own research and consult with a qualified financial professional before making any investment decisions.
